Search
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnCyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.
Colestilan chloride
go.drugbank.com/drugs/DB11634ApprovedWithdrawnColestilan is an ingredient in the EMA-withdrawn product BindRen.
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaEquine Botulinum Neurotoxin G Immune FAB2
go.drugbank.com/drugs/DB13899ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.
Equine Botulinum Neurotoxin D Immune FAB2
go.drugbank.com/drugs/DB13902ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.
Scorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedSevere scorpion stings may cause loss of muscle control and respiratory failure, warranting heavy sedation and hospitalization in an intensive care unit. … Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483].
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSetiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Viper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]